ClinicalTrials.gg

Program

monalizumab

Also written as “Monalizumab”, “NNC 0141-0000-0100” and “Durvalumab + Monalizumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Colonic Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell, led by 2 companies.

Furthest: phase 3, since Sep 23, 20209 company-led studies, 3 open or runningNext primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca53 open or runningphase 3since Sep 23, 2020Dec 10, 2018Jan 8, 2027phase 3 · NCT05221840
Innate Pharma40 open or runningphase 2since Jan 2, 2015May 31, 2011none ahead
  • Named in AstraZeneca’s own pipeline as monalizumab, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2011First study: phase 1 study in InflammationNew to Innate PharmaInnate Pharma · NCT01370902 · 92 enrolled · Germany
  2. Jan 2, 2015Phase 2 study in Squamous Cell Carcinoma of Head and NeckInnate Pharma · NCT02331875 · 3 enrolled · Germany, Spain
  3. Sep 22, 2015Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellInnate Pharma · NCT02557516 · 22 enrolled · United States
  4. Dec 17, 2015Phase 2 study in Head and Neck NeoplasmsInnate Pharma · NCT02643550 · 143 enrolled · United States, France
  5. Dec 10, 2018AstraZeneca's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT03822351 · 189 enrolled · United States, Canada, France and more
  6. Oct 16, 2019Phase 2 study in Colonic NeoplasmsAstraZeneca · NCT04145193
  7. Sep 23, 2020Phase 3 study in Squamous Cell Carcinoma of Head and NeckAstraZeneca · NCT04590963 · 370 enrolled · United States, Argentina, Australia and more
  8. Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05061550 · 630 planned · United States, Belgium, Canada and more
  9. Jan 14, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05221840 · 1,051 enrolled · United States, Australia, Brazil and more
  10. Nov 4, 2026Primary completion moved from 2026-09-30 to 2027-01-08Date moved laterphase 3 · +3 months · NCT05221840

Ahead

  1. Jan 8, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05221840
  2. May 28, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05061550

TargetBeta

“A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prev…”NCIt, read by Claude

Other programs on KLRC1

ProgramCompanyFurthest phaseStudies
Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628ruleExelixisphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05221840Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingAstraZenecaJan 8, 20271,051
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingAstraZenecaMay 28, 2030630
NCT04590963Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3Active, not recruitingAstraZenecaMay 11, 2022370
NCT04145193Colonic Neoplasms2WithdrawnAstraZenecaMar 19, 20240
NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedAstraZenecaJul 18, 2023189
NCT02643550Head and Neck Neoplasms · United States, France2CompletedInnate PharmaMar 28, 2023143
NCT02557516Leukemia, Lymphocytic, Chronic, B-Cell · United States2TerminatedInnate PharmaOct 29, 201822
NCT02331875Squamous Cell Carcinoma of Head and Neck · Germany, Spain2TerminatedInnate PharmaDec 20163
NCT01370902Inflammation · Germany1CompletedInnate PharmaMar 201492

How it is read

Names in the registry

  • “Monalizumab”, 4 entries
  • “NNC 0141-0000-0100”, 3 entries
  • “Durvalumab + Monalizumab”, 1 entry
  • “E3 - mFOLFOX6, durvalumab and monalizumab”, 1 entry
  • “monalizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.